For the Treatment of Moderate to Severe Psoriasis, the Highest Proportion of Surveyed Dermatologists and MCOs Indicate That Humira and Enbrel Have the Best Overall Clinical Profile When Compared to Other Currently Available Agents
Monday, February 07, 2022 10:31 AM

Related Stories



However, Nearly Half of Surveyed Dermatologists Chose Remicade as

the Most Efficacious Therapy for Moderate to Severe Psoriasis,

According to Findings from Decision Resources

Feb. 7, 2011 (Business Wire) -- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations’ (MCOs) pharmacy directors indicate that Abbott/Eisai’s Humira and Amgen/Pfizer/Stiefel/Takeda’s Enbrel have the best overall clinical profile when compared to other currently available agents. However, when asked to identify which available psoriasis agent was the most efficacious, most surveyed MCO pharmacy directors chose Humira or Enbrel while nearly half of surveyed dermatologists chose Centocor Ortho Biotech/Merck/Mitsubishi Tanabe’s Remicade.

The findings from Decision Resources’ analysis of the psoriasis drug market reveal that surveyed dermatologists who selected Remicade as the most efficacious agent reported higher satisfaction with the drug’s effect on psoriatic plaques at ten or 12 weeks than with any other efficacy attribute. In contrast, when asked to identify the most efficacious psoriasis therapy, surveyed MCO pharmacy directors identified Humira (45 percent) or Enbrel (41 percent), while only nine percent of surveyed MCO pharmacy directors selected Remicade. Additionally, despite robust efficacy data from clinical trials, only 13 percent of surveyed dermatologists selected Centocor Ortho Biotech/Janssen-Cilag’s Stelara—the first IL-12/23 inhibitor to launch for the indication—as the most efficacious therapy for moderate to severe psoriasis.

Although Enbrel, the current market leader in psoriasis, was selected as the most efficacious therapy by a slightly higher percentage of surveyed dermatologists than its closest competitor, Humira, the report findings suggest that Enbrel’s market position is at risk.

“Surveyed dermatologists who consider Enbrel the most efficacious drug gave it lower satisfaction scores on most efficacy attributes compared with the scores awarded to Humira by the surveyed dermatologists who selected it as the most efficacious,” said Decision Resources Therapeutic Area Director Madhuri Borde, Ph.D. “This perception of Enbrel’s inferior efficacy compared with other agents in its class is supported by clinical trial data.”

The findings also reveal that surveyed experts agree that long-term response with continuous therapy is one of the attributes that most influences their prescribing and tier placement decisions in moderate to severe psoriasis. Clinical data and the opinions of interviewed thought leaders indicate that Stelara has advantages on this attribute over Enbrel.

The continued uptake of interleukin inhibitors and TNF-alpha inhibitors and an almost twofold increase in the penetration of biologics in the moderate-to-severe population will drive a robust increase in the psoriasis drug market, from $3.4 billion in 2009 to more than $6.1 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Although Enbrel maintained its market dominance in 2009, it will face stiff competition from Humira and Stelara, which—along with the entry of biosimilar formulations—will lead to a decline of Enbrel’s market share from more than one-third of sales in 2009 to less than one-fifth of sales in 2019.

Decision Resources’ Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2011 advisory service and the DecisionBase 2011 report series.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
ccomfort@dresources.com


(Source: Business Wire )
(Source: Quotemedia)
 

Sponsors

Symbol :

Advertisement

Market news:

  • Pitney (NYSE: PBI) Q4 Revenue Declines 1 Percent Feb 09, 2022 05:20 PM

    Pitney Bowes Inc. (NYSE: PBI) reported its fourth quarter 2010 revenue of $1.4 billion, a decline of 1 percent as compared the fourth quarter of 2009. GAAP net income for the quarter was $63 million or $0.31 per share as compared to $$98.5 million or $048 per share in the fourth quarter of 2009.

  • MetLife, Inc. (NYSE: MET) Q4 Net Income Falls on Derivative Loss Feb 09, 2022 05:20 PM

    MetLife, Inc. (NYSE: MET) reported fourth quarter 2010 net income of $51 million, or $0.05 per share, and operating earnings of $1.2 billion, or $1.14 per share. Derivative losses drove most of the difference between net income and operating earnings in the fourth quarter of 2010.

  • Akamai (NASDAQ: AKAM) Q4 Income Rises 32 Percent Feb 09, 2022 05:20 PM

    Akamai Technologies, Inc. (NASDAQ: AKAM), reported net income of $52.5 million or $0.27 per diluted share, a 32 percent increase for the fourth quarter of 2010 as compared to $40.1 million or $0.21 per diluted share in the fourth quarter of 2009.

  • Strokes are rising fast among young, middle-aged Feb 09, 2022 05:18 PM

    • LOS ANGELES - Strokes are rising dramatically among young and middle-aged Americans while dropping in older people, a sign that the obesity epidemic may be starting to reshape the age burden of the disease.
    • The numbers, reported Wednesday at an American Stroke Association conference, come from the first large nationwide study of stroke hospitalizations by age.
    • Strokes rose among women in this age group, too, but not as fast - 17 percent.
      • Challenging Obama, House GOP calls for deep cuts Feb 09, 2022 05:18 PM

        • WASHINGTON - Eager to take a quick, $35 billion bite out of government, House Republicans called for termination of at least 60 federal programs Wednesday and cuts in hundreds of others, targeting education and the environment, food safety and law enforcement.
        • The government's principal nutrition program for pregnant women would be cut 6 percent below last year's level.
        • Republicans are "keeping our pledge to the American people that we will cut spending," said House Speaker John Boehner, R-Ohio, after details were outlined for the rank and file at a closed-door meeting.

          More news


Advertisement

    Recent Estimates

AnalystFirm NameSymbolEPS Estimate
XXXXXXXXXX PMI($0.65)
XXXXXXXXXX SLW$0.28
XXXXXXXXXX ATVI$0.49
XXXXXXXXXX CGNX$0.43
XXXXXXXXXX LVS$0.38
XXXXXXXXXX NFLX$0.71
ABN SkateNFC AMZN$0.88
XXXXXXXXXX AKAM$0.28
XXXXXXXXXX LVS$0.38
ASAS BAC$0.19